506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents

NCT00003635 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

DRUG: nelarabine

Sponsor

GlaxoSmithKline

Collaborators

[object Object]